Core Viewpoint - The company has entered into a non-binding term sheet with PDC in the UAE for the exclusive licensing of its product Visepegenatide (PB-119), a GLP-1 receptor agonist for type 2 diabetes and weight management, marking a significant milestone in its global commercialization strategy [1][2] Group 1 - The agreement grants PDC exclusive rights to develop, distribute, market, and commercialize PB-119 in the Middle East and Africa, including local production and comprehensive technology transfer [1] - The partnership is strategically important as PDC's extensive regional expertise and infrastructure can accelerate market access and penetration, validating the company's asset output strategy [1][2] - The Middle East and Africa represent a large and growing market for diabetes and obesity treatment, highlighting the unmet medical needs and commercial potential for innovative therapies like PB-119 [1] Group 2 - PDC is a leading pharmaceutical R&D institution in the region with a strong track record in clinical trials, providing end-to-end innovative solutions for clinical studies and life sciences [2] - The collaboration with PDC reinforces the company's proprietary R&D capabilities and the clinical characteristics of Visepegenatide (PB-119), showcasing its significant market potential [2] - This partnership is a crucial step in expanding the global footprint of PB-119 and aligns with the overall interests of the company and its shareholders [2]
派格生物医药-B(02565.HK)拟向阿联酋PDC授出Visepegenatide (PB-119)于中东及非洲的独家许可